A Phase 1/2 study of the safety, tolorability and efficacy of INCB24360 administered in combination with Nivolumab in select advanced cancers.

Administered By

Duke Cancer Institute

Awarded By

Incyte Corporation

Contributors

Mettu, Niharika Bansal Principal Investigator

Start/End

April 1, 2015 - March 30, 2020